Answers are grounded in this paper and cite their sources.
Capmatinib showed substantial antitumor activity in patients with advanced NSCLC with a MET exon 14 skipping mutation, particularly in those not treated previously. The efficacy in MET-amplified advanced NSCLC was higher in tumors with a high gene copy number than in those with a low gene copy number. Low-grade peripheral edema and nausea were the main toxic effects. (Funded by Novartis Pharmaceuticals; GEOMETRY mono-1 ClinicalTrials.gov number, NCT02414139.).
No takes yet. Share an insight, caveat, or question.
Wolf et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: